SMN2 and proximal spinal muscular atrophy: Indeed, future clinical investigations of fatty acid metabolism defects in SMA patients treated with SMN gene-based therapies will be essential to better understand the nature of the metabolic perturbations and the contribution of different CNS and peripheral tissues to the fatty acid metabolism defects.